Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of belinostat when given
together with azacitidine in treating patients with advanced hematologic cancers or other
diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy,
such as azacitidine, work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing. Giving belinostat together with
azacitidine may kill more cancer cells.